POTENTIAL PROTECTIVE EFFECTS OF ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKADE IN ALZHEIMER RAT MODEL

Atef M. Abood¹,²

ABSTRACT

Background: Alzheimer disease (AD) and Alzheimer type dementia (ATD) represent major health problem in aged population. AD is characterized by memory impairment, exaggerated oxidative stress and decrease antioxidant capacity. Angiotensin II and angiotensin II type 1 and type 2 receptors (ATR₁ and ATR₂) are incriminated in the pathogenesis of AD.

Aim of the work: This study was carried out to investigate the effect of angiotensin II type 1 receptor blockade on memory function in AlCl₃-induced Alzheimer in rats.

Materials and methods: Thirty animals in this study were divided into five equal groups. Group 1: control rats. Group II: Alzheimer model, the rats were intraperitoneally injected with 40 mg / kilogram body AlCl₃ for 4 weeks group III: ATR₁ blocker-treated AD-group: animals were injected telmisartan in a dose of 1mg/kg. by oral gavage for 8 weeks and for the last 4 weeks were injected AlCl₃. Group 4: Donepezil-treated AD-group: rats were given Donepezil 5 mg/kg orally for 8 weeks and for the last 4 weeks were injected AlCl₃. Group 5: ATR₁ blocker-donepezil treated AD group. After the 8 weeks, animals were suspected to short term memory testing using the Novel Object Recognition test interpreting the discrimination index (DI), Recognition index (RI), frequency of exploration and locomotor activity. Malondialdehyde (MDA), Glutathione (GSH) and glutamate contents of cerebral cortex and hippocampus homogenates were biochemically assayed.

Results: AlCl₃-treated group showed impaired short-term memory indices and locomotor activity with increased MDA and decreased GSH as well as glutamate content in cerebral cortex and hippocampus. ATR₁ blocker-treated group showed significant improvement in memory function, decreased MDA and increased GSH as well as decreased glutamate content. In ATR₁ blocker plus donepezil-tREATED group the effects of both drugs were additive and parallel.

Conclusion: ATR₁ blockade improved memory function in ATD induced by AlCl₃ injection in rats and exerts antioxidant and anti-excitotoxic effects.

Key words Alzheimer disease – Memory function – Angiotensin II type one receptors (ATR₁) – Telmisartan.

INTRODUCTION:
AD is a very common cause of dementia. Alzheimer type dementia (ATD) represents more than 50% of causes of dementia. Memory loss with insidious onset and progressive course represents the early manifestations of ATD(1). Multiple pathologic mechanisms are underlying AD.
Enhanced oxidative stress and accumulation of reactive oxygen species (ROS) molecules feature the AD(2). ROS molecules have been shown to enhance A beta amyloid (Aβ) generation, misfolding, and aggregation(3), overwhelming lipid peroxidation(4), as well as decline in antioxidant mechanisms(5). The brain neurotransmitter systems are also disturbed in cases of memory impairment and ATD. Glutaminergic, serotonergic in addition to the well settled cholinergic transmitters are modulated(6).

Angiotensin II, the main biologically active peptide of the Renin Angiotensin system (RAS) and its receptors have been identified in many brain regions including the cortex and hippocampus(7). Several studies have been conducted to evaluate the role of ang II and its receptors in brain cognitive functions. Although a positive effect of ang II on memory function was reported earlier(8), a negative effect of angiotensin II on memory reported later in a more detailed study by Tota et al.,(9). A lot of work about the effect of RAS system on memory function have been extrapolated through studies on angiotensin II receptors. It was suggested that a direct ATR2 receptor agonist, enhances cognitive function(10). Moreover, the ATR1, losartan exerted potent preventive and restorative effects on AD hallmarks, possibly by mitigating AT1-initiated oxidative stress and normalizing memory-related AT4 receptors(11).

When the Ang II is infused into the hippocampus, it produced a dose dependent amnesic effect with inhibitory avoidance task in rats(12). Furthermore, administration of Ang II disrupted retrieval of aversive memory in the inhibitory avoidance task(13).

The exaggerated activity of the brain RAS in neurodegenerative diseases(14) and AD(15&16), makes the RAS system and its receptors an important target in researches about AD.

AIM OF THE WORK:

The aim of this study is to investigate the effect of angiotensin II type 1 receptors blockade on the memory function in a rat model of Alzheimer induced by AlCl3 injection.

MATERIALS AND METHODS:

Animals:

This study was carried out on 30 male Wistar rats 5-6 months old (200-250 gm body weight). Animals were kept under standard conditions of boarding in cages of 5 rats each. The rats were allowed free access to water and ad libitum feeding except before drug administration. The study was approved by ethical committee of KAU (199-311). It conforms to the NIH guidelines for the care of use of laboratory animals.

Experimental protocol:

Animals in this study were divided into 5 groups 6 rats each. Group 1: control rats; Group II: Alzheimer model (AD), the rats in this group were injected by the 0.5% methylcellulose in the first 4 weeks and then injected AlCl3 (Sigma Aldrich UK) dissolved in saline and given as IP injection in a dose of 40 mg / Kg body weight for another 4 weeks(17-19). Group III: ATR1 blocker-treated group: animals in this group were injected telmisartan (Boehringer Ingelheim) 1mg was dissolved in 0.5 % methylcellulose at a concentration of 1mg/1ml, the drug was then given in a dose of 1mg/kg, by oral gavage for 8 weeks the first 4 weeks given the ATR1 blocker plus saline and the next 4 weeks were given ATR1 blocker plus AlCl3 in a similar manner to group II.

The dose of 1 mg of this blocker were chosen on basis of optimal action as it is considered normotensive and so does not affect the cerebral blood flow(20). Group 4:
Donepezil-treated AD group, rats were given the cholinomimetic agent Donepezil 5 mg/kg orally\(^9\), for 8 weeks the first 4 weeks given the donepezil plus saline and the next 4 weeks were given donepezil plus AlCl\(_3\). Group 5: Alzheimer ATR\(_1\) blocker donepezil-treated AD group, the animals were injected by both ATR\(_1\) blocker and donepezil by the same dose and route of group 3 and 4 for 8 weeks. The first 4 weeks were injected by saline and the next 4 weeks were additionally injected by AlCl\(_3\). All groups are injected by the vehicle in the same dose and route of administration. The experimental protocol is shown in table 1.

Table 1: The experimental protocol of this study.

<table>
<thead>
<tr>
<th>Group</th>
<th>First 4 weeks</th>
<th>Next 4 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>I (control)</td>
<td>Vehicle</td>
<td>Vehicle</td>
</tr>
<tr>
<td>II (Alzheimer model)</td>
<td>Vehicle</td>
<td>40 mg/kg AlCl(_3)</td>
</tr>
<tr>
<td>III (ATR(_1) blocker- AD)</td>
<td>ATR(_1) blocker</td>
<td>1mg/kg ATR(_1) blocker (telmisartan) + AlCl(_3)</td>
</tr>
<tr>
<td>IV (Donepezil-treated AD)</td>
<td>Donepezil</td>
<td>Donepezil + AlCl(_3)</td>
</tr>
<tr>
<td>V (ATR(_1) + donepezil-treated AD)</td>
<td>Donepezil + ATR(_1) blocker (telmisartan)</td>
<td>Donepezil + ATR(_1) blocker (telmisartan) + AlCl(_3)</td>
</tr>
</tbody>
</table>

**Assessment of short term memory by novel object recognition test (NOR):**

The NOR test is largely accepted as an indicative test for memory impairment\(^21\). The test was performed in sound insulated room and the objects used for recognition should have criteria specified before to be attractable and easily cleaned as well as odorless. Two identical objects are placed in the arena and rats were allowed to explore both objects for 3 minutes 15 minutes later one of the familiar objects were replaced by a new one\(^22\). Animals were given another 3 minutes to explore and the results were recorded regarding the following:

- Frequency of exploration within the 3-minute period for both the new and old objects.
- The time of exploration of the familiar (TF) and of the novel object (TN).
- The DI: discrimination index: was calculated as follows: DI = TN-TF/TN + TF. The positive values for DI indicate a longer time for the exploration of new objects while negative values indicate a longer time for exploring the familiar objects which reflects memory impairment.
- Distance moved by the animal during the 3-minute period\(^22-24\).

Another measure of the object recognition task is R (recognition) index which is the time spent to explore the novel object relative to the both objects exploration time and calculated as R = TN/TNF\(^24\).

All rats were submitted to two habituation sessions, with a 1-h interval, whereby they were allowed exploration of the apparatus 3 minutes for each session. The test sessions began 24 hours later.

Ethovision XT8A a video tracking system was used to automatically record the results and calculate the different parameters. The vision XT8A, also, records the total distance moved in centimeters and the frequency and duration of the nose point sniffing the familiar and novel objects.

**Brain tissue preparation:**

After the behavioral test, the rats were gently decapitated following the guidelines and regulation of KAU ethical unit. After dissection, their whole brains were removed carefully and washed in saline and divided in a sagittal plane into two halves. The Hippocampus and prefrontal cortex were dissected and immediately deep-frozen in hexane and dried ice and maintained in −80°C for tissue homogenate assays.
The glutamate, malondialdehyde (MDA), and glutathione (GSH) levels were estimated in their homogenates by quantification ELIZA kits (Abcam; Cambridge, UK) following the company’s recommended protocol\textsuperscript{25}.

**Statistical analysis:**

Data were expressed as mean ± SEM. The Student’s t-test for paired and unpaired data was performed to assess them as statistically significant intragroup and intergroup differences, respectively. All statistical data and statistical significance were analyzed using the Statistical Package for Social Sciences (SPSS Inc., Chicago, Illinois, USA), version 16. A P value less than 0.05 was considered statistically significant.

**RESULTS:**

*Results of NOR test and motor activity (figures 1-3) and table 2:*

In the figure 1 and 2, the Alzheimer model group showed significant deterioration of memory parameters of NOR test. DI was significantly lower in AlCl3 treated group (-0.11 ± 0.04); as compared to control group 0.31 ± 0.11 P < 0.001). Similarly, The R index was also significantly reduced in AlCl3 treated group (0.44 ± 0.02) compared to non-treated control (0.66 ± 0.06 P < 0.01).

ATR\textsubscript{1}-treated group showed significant increase in the DI (0.18 ± 0.06) and RI (0.59 ± 0.03) as compared to Alzheimer non-treated group (-0.11 ± 0.04 and 0.44 ± 0.02 respectively P < 0.05). Similar elevation in DI and RI were found in Donepezil treated group (0.20 ± 0.09 and 0.60 ± 0.05 respectively P < 0.01). DI and RI were also significantly elevated in animals treated with both ATR\textsubscript{1} blocker and donepezil (0.25 ± 0.09 and 0.63 0.05 respectively P < 0.0001).

Figure (1) NOR test results. The means and standard deviations (SD) of the difficulty index of the studied groups. *significant from the control group for unpaired data P < 0.05. *significant from AD group for unpaired data.
potential protective effects of angiotensin ii type 1 receptor blockade in alzheimer rat model

Figure (2) NOR test results: The means and standard deviations (SD) of the Recognition Index (RI) of the studied groups. *significant from the control group for unpaired data P<0.05. #significant from AD group for unpaired data.

In table 2, the control group, the frequency of exploration (F) of the new object was significantly higher in control group (10.21.47 as compare to familiar object (5.17 ± 1.17, P<0.01. This statistical pattern was lost in AlCl3 treated group 9 ± 1.41 vs 8.17 ± 1.17 for new and old objectives respectively. Although the frequency of exploration in Alzheimer group treated with ATR1 blocker was higher for new object compared to old one the elevation was not statistically significant 8.17 ± 1.47 vs 7.33 ± 1.03 respectively. Statistical results as regard frequency of exploration were significantly higher for new objects vs old one in Donepezil treated Alzheimer model 9.33 ± 1.21 of new object vs 5.5 ± 1.05 as well as in ATR1 blocker and donepezil treated animals 9.83 ± 0.75 vs 5.83 ± 1.17 P<0.0001.

Table 2: The means and standard deviations (S D) of Frequency of exploration (F) of novel and familiar objects in the studied groups. *significance difference of frequency of exploration of novel and familiar objects. P<0.05.

<table>
<thead>
<tr>
<th>Group</th>
<th>F for novel object</th>
<th>F for familiar object</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>5.17 ± 1.17</td>
<td>10.2 ± 1.47*</td>
</tr>
<tr>
<td>AD</td>
<td>10.2± 1.43</td>
<td>8.17 ± 1.17</td>
</tr>
<tr>
<td>ATR1-treated AD</td>
<td>8.17 ± 1.47</td>
<td>7.33 ±1.03</td>
</tr>
<tr>
<td>Donepezil-treated AD</td>
<td>9.33 ±1.21</td>
<td>5.5 ± 1.05*</td>
</tr>
<tr>
<td>ATR1 and Donepezil-treated AD</td>
<td>9.83 ± 0.76</td>
<td>5.83± 1.17*</td>
</tr>
</tbody>
</table>

As regard the total distance moved by the animals in the 5- minute duration test, Figure 3 showed that the total distance was significantly reduced in the AlCl3 treated group compared with control group 578 ± 847. vs 860 ± 86 P<0.0001. On administration of ATR1 blocker no significant changes in the distance moved compared to AD group. However, donepezil group (Mean ± SD:796 ± 85) or ATR1+donepezil group (Mean ± SD: 833 ± 70) shows significant increase in the distance moved as compared to AD group (Mean ± SD:578 ± 84) P<0.001 for both groups.
Biochemical results:

The glutamate content in brain tissue homogenates (figure 4):

The glutamate content of the prefrontal cortex and hippocampus were significantly higher in AlCl3-treated rats (12.5 ± 2.43 and 10.5 ± 1.64) as compared to control group (8.83±1.47 and 7.67 ± 1.3) P <0.5 and P<0.1 respectively.

In AlCl3 treated animals, administration of ARB was associated with significant reduction of glutamate content in the prefrontal cortex (9.83 ± 1.17) P<0.05 but not in the hippocampus (9.17 ± 1.94).

On the other hand, Donepezil administration to AlCl3 injected animals did not show significant change in glutamate content of either prefrontal cortex (9 ± 1.41) or hippocampus (8.83 ± 1.47).

The effect of administration of both donepezil and ARB simultaneously to AlCl3-treated animals was manifested in the form of significant decline of glutamate content in both prefrontal cortex (7.17 ± 1.41) and the hippocampus 8 ± 1.29 (P <0.001 and P<0.05) respectively.
**potential protective effects of angiotensin ii type 1 receptor blockade in alzheimer rat model**

*MDA content in brain tissue homogenates*

Figure 5:

The MDA content of the prefrontal cortex and hippocampus homogenates were significantly higher in AlCl3-treated rats (30.3 ± 3.33 and 232 ± 4.38) as compared to control group (10.83 1.47 and 8.5 ± 1.87) P <000.1. In AlCl3 treated animals, administration of ARB was associated with significant reduction of MDA content in the prefrontal cortex (20.5± 3.02) P<0.001, but not in the hippocampus (23.2 ± 5.98).

![Figure 5](image)

**Figure 5:** The MDA content of both the cerebral cortex (CC) and the hippocampus (Hippo) tissue homogenates expressed as mean ± SD. #significant from the control group for unpaired data P<0.05. *significant from AD group for unpaired data

Similarly, Donepezil administration to AlCl3 injected animals showed significant decrease in MDA content of the prefrontal cortex (17.7 ± 3.27) P<0.001, but not in the hippocampus (18.8 ± 7.08). The effect of administration of both donepezil and ARB simultaneously to AlCl3-treated animals was manifested in the form of significant decline of glutamate content in both prefrontal cortex (12.5 ± 2.65) and the hippocampus (16.5 ± 4.97, P <0.001 and p<0.05 respectively.

**GSH content in brain tissue homogenates (figure 6):**

The GSH content of the prefrontal cortex and hippocampus homogenates were significantly lower in AlCl3-treated rats (15.3 ± 3.14 and 17 ± 2.61) as compared to control group (25.8± 5.42 and 21.5± 3.21) P <000.1. In AlCl3-treated animals, administration of ATR1 blocker was associated with significant elevation of GSH content in the prefrontal cortex (21.7 ± 3.93) P<0.05 and the hippocampus (20.8 ± 3.06) P<0.05.

On the contrary, Donepezil administration to AlCl3 injected animals showed no significant changes in the GSH content of the prefrontal cortex (20.8 ± 5.43) and the hippocampus (19.3± 2.07). The effect of administration of both donepezil and ARB together to AlCl3-treated animals was associated with significant increase of GSH content in both prefrontal cortex (28 ± 5.56) and the hippocampus (22 ± 3.40) P <0.05 for both values.
**DISCUSSION:**

The AlCl₃-injected rats showed the features of ATD. Impairment of short-term memory is evidenced by the results of Novel Object Recognition (NOR) test. The data of this group of animals clearly showed significant lowering of DI and RI, higher frequency of exploration for old objects, as well as impairment of locomotor activity. This pattern of memory impairment in our study is previously described in Alzheimer diseases(26&27).

Our data represented other pathological features of AD in AlCl₃-treated rats. Enhanced oxidative stress and high level of lipid peroxidation products with concomitant drop of antioxidant GSH in brain regions presented in this work conform to the results of other investigators(2,5&28). Furthermore, we demonstrated exaggerated glutamate content in both cerebral cortex and hippocampus of rats treated with AlCl₃. The result confirms the suggestions that glutamate excitotoxicity is an early feature of AD (29&30).

The use of ATR₁ blocker (telmisartan) four weeks before and during the next four weeks of AlCl₃ administration revealed a potential improvement of the induced-ATD. AD group expressed minimal memory impairment through ORT, less accumulation of lipid peroxidation products, higher GSH and lower glutamate contents of cerebral cortex homogenates. Our results show that ATR₁ blockade parallel and potentiate the role of the common cholinomimetic agent donepezil, commonly used in treatment of AD.

Improvement of memory function by AT1R blockers was reported by many investigators(9,12). Furthermore, Angiotensin II is reported to inhibit acquisition, consolidation and recall of memory and this inhibition is blocked by AT1R blocker(9&12). Our results are contradicted however, to the results obtained by Braszko(8), who showed memory improvement by intracerebroventricular (ICV) injection of angiotensin II and this improvement is abolished by ATR₁ blocker losartan. This contradiction could be explained by the methodological difference like dose of angiotensin injected, dose and formula of ATR₁ blockers used and the test used to examine the memory.
The memory improvement by ATR₁ blocker in our experiment due to blocking the overactivity of RAS components in AD, a finding that is supported by clinical and preclinical studies\(^{(15,16)}\). Exaggerated levels of ACE₁, angiotensin II and ATR₂ in neuro degenerative diseases is recently reported\(^{(14,32)}\). RAS overactivity is also a feature of LPS-induced memory impairment in spontaneously hypertensive rats. There are increased levels of angiotensin II, ACE, and ATR₁ levels\(^{(26)}\). Moreover, AT1R overexpression is a common feature of many brain disorders and a major mechanism of vascular dysfunction\(^{(33)}\). There are a strong association between angiotensin II levels and Aβ amyloid and tau protein contents in the brain \(^{(14,32)}\). The ICV injection of angiotensin II has a negative impact on memory function \(^{(9)}\). The prophylactic effect of ATR₁ blocker is a natural consequence due to blocking the deleterious effects of exaggerated angiotensin II. The ATR₁ blockade protects against cellular damage and mitochondrial energy flow\(^{(34)}\).

It is worth to say that ATR₂ have an opposite role to ATR₁ where it protects the brain against oxidative and inflammatory states that characterize AD\(^{(26)}\). Thus, ATR₁ blocker produces its positive effect indirectly through increased activity of ATR₂. ATR₂ activity directly improves spatial memory in AD mouse model. The ATR₂ agonist potentiated memory function and accentuated the excitatory post synaptic potential and neuronal growth in the hippocampus\(^{(10)}\). Eventually, the prophylactic effect of ATR₁ blocker could be seen in the view of counteraction between the harmful ATR₁ and the beneficial ATR₂ in the brain. Blocking the ATR₁ shifts the balance towards ATR₂ which represents the protective axis of the RAS system in the brain\(^{(26)}\).

Some authors attribute the beneficial effects of ATR₁ blocker at least partly to the blood pressure lowering effect and the increased cerebral blood flow\(^{(35)}\). However, the dose and type of ATR₁ blocker used in our study is not hypotensive\(^{(26)}\).

Our results revealed exaggerated oxidative status. Oxidative stress and impaired energy metabolism have long been associated with pathophysiology of memory impairment\(^{(36)}\). It is considered as one of the main pathologic mechanisms of AD \(^{(37)}\). Mitochondrial dysfunction, Abeta amyloid accumulation and inflammation act as different sources of free radical generation in AlCl₃-induced brain toxicity\(^{(37)}\).

Our results revealed improved oxidative features of rats treated by ATR₁ blocker. The significant reduction of lipid peroxidation products and the elevation of the antioxidant GSH may explain the memory protection. Several studies showed that Ang II induces free radicle generation an effect that is mediated by ATR₁\(^{(9)}\). The ATR₁ blockers oppose this effect\(^{(38,39)}\). The antioxidant effect of ATR₁ blockade could be attributed to the well-known antioxidant effect of ATR₂\(^{(40)}\).

Exaggerated glutamate content is considered an early feature of ATD\(^{(29)}\). Moreover, AD is associated with disturbed glutamate uptake and hence glutamate excitotoxicity\(^{(41)}\). Furthermore, overactiveion of NMDA and AMPA receptors impair memory and learning mechanisms \(^{(24)}\), and act as basis for many neurodegenerative diseases\(^{(42)}\).

Finally, the role of ATR₁ blockade in ameliorating the excitotoxic effect of excessive glutamate is evident in our study by the decrease glutamate content in brain tissue homogenates in both cerebral cortex and hippocampus. This ability of ATR₁ to block glutamate excitotoxicity seems to be a new finding in our study.

In conclusion, our study presented an ATD induced by AlCl₃ injections. ATR₁ blockade ameliorated memory function through impairment of oxidative status and
increasing antioxidant mechanisms in addition to exerting anti-excitotoxic effect. This evidence of beneficial effect of ATR1 blockade would suggest a therapeutic potential in ATD patients.

REFERENCES


potential protective effects of angiotensin ii type 1 receptor blockade in alzheimer rat model


الدور الفعال لمضادات مستقبلات النجيوتنسين من النوع الثاني في مرض الألزهایمر في الفئران

د. عاطف عبد

يعتبر الألزهایمر من الأمراض النفسية الأكثر شعبية في العالم. ويتضمن هذا النوع من الأمراض صعوبة الإجابة على الأسئلة المتصلة بها وما ينتج عن وجوده. وتشمل الأمراض البيولوجية المعروفة للاختبار؟

تتألف معدل الأكسيد ونقص التفاعلات الهامة للانستاتيين من مستقبلات الأنسولين البارعة في جسم الإنسان، ولهذا يُعتبر تأثيره في الأداء في هذا الحجم مهمًا. واننا نحتاج إلى اتخاذ إجراءات في تلك الحالة لتحسين الأداء في صحة الإنسان.

تتم استخدام ثلاثون فارا من الذكور من نوع الألبانز يتراوح وزنها بين 200 و 250 جرام وقد قسمت إلى 5 مجموعات متساوية وجمعتها ثم حققت بالألومينيوم كلوستي مبيضياً وجميعها في اتباع الإصدار والمجوعات الثلاث الأخرى. شملت مجموعة الاستثمار مستقبلات الأنسولينية البارعة التي تتأثر بعد اتباع أخرين، بالإضافة إلى حساسية المواد وكمياتها، وتم تحقيق النتائج بالتعاون مع مجموعة أخرى من الفائنين مضافات الأنسولينية من النوع الأول والدوتين في محاولة تحسين الأداء في هذا المجال.

وقد أظهرت النتائج أن حقن الفئران بمادة الألبانز كلوستي ب 0.5 مجم لكل كيلوغرام من وزن الفئران لمدة 3 أسابيع HUDI مختلف علاجات خاصة لمرض الألزهایمر بتأثيرها في الجاذب الذي تم اختياره باختيار التعرف على الجهاز الجديد للانستاتيين بالإضافة إلى زيادة ذالله احساسها في مؤشرات الاختبار كمعظم الصعوبات ويعمل التعرف وتكريمة استكشاف الجسم الجديد. أيضا تتميز الفئران المحفوفة بالألبانز كلوستي بوجود زيادة في معدل الأكسدة ونقص مضاداتها وتراكم الناقل العصبي الجلوتاماتي في القشرة المخية للانستاتيين المحفوضة.

و عند التحق علاجات الانستاتيين النوع الأول تّحسنت معظم علامات الألزهایمر مثل تخسي الذاكرة وتقص الاكسدة وتكافك الجلوتاماتي. ونتيجة من ذلك أن مضادات مستقبلات الأنسولينية من النوع 2 مفيد في تخسي الذاكرة وتخفيف الاكسدة ونقص في معدل تراكم الناقل العصبي الجلوتاميت.